What is the recommended management for asthma?

Management of Asthma

All adults and adolescents with asthma should receive inhaled corticosteroid (ICS)-containing therapy, not short-acting beta-agonist (SABA) monotherapy alone, to reduce severe exacerbations and mortality. 1, 2

Stepwise Treatment Approach

Step 1: Mild Intermittent Asthma

• Preferred: As-needed low-dose ICS-formoterol for patients with occasional symptoms (<2 times/month, no nocturnal symptoms, FEV1 >80% predicted) 3
• This approach significantly reduces moderate-to-severe exacerbations compared to SABA alone 4, 3

Step 2: Mild Persistent Asthma

• Preferred: As-needed low-dose ICS-formoterol (anti-inflammatory reliever therapy) 3, 2
• Alternative: Daily low-dose ICS plus as-needed SABA 5
• The as-needed ICS-formoterol approach is superior to SABA monotherapy for preventing exacerbations 4

Step 3: Moderate Asthma

• Preferred: Daily low-dose ICS-LABA (long-acting beta-agonist) combination 5, 6
• Alternative: Medium-dose ICS alone, or low-dose ICS plus leukotriene receptor antagonist 5
• ICS-LABA combinations demonstrate synergistic anti-inflammatory effects equivalent to or better than doubling the ICS dose 3

Step 4: Moderate-Severe Asthma

• Preferred: Medium-to-high dose ICS-LABA, ideally as Maintenance and Reliever Therapy (MART) with ICS-formoterol 1, 2
• Alternative: Add leukotriene modifier, theophylline, or long-acting muscarinic antagonist (LAMA) 4, 5
• Adding LABA to ICS is superior to all other combinations and to higher ICS doses alone 7

Step 5: Severe Asthma

• Preferred: High-dose ICS-LABA-LAMA (triple therapy) 3
• Triple combination inhalers improve symptoms, lung function, and reduce exacerbations when asthma remains uncontrolled on medium-to-high dose ICS-LABA 3
• Consider adding tiotropium as the LAMA component 4, 6

Step 6: Severe Uncontrolled Asthma

• Preferred: Add biologic therapy for type 2 inflammation (elevated eosinophils ≥150/μl, FeNO ≥35 ppb, or elevated IgE) 3
  • Anti-IgE (omalizumab)
  • Anti-IL-5 (mepolizumab, reslizumab)
  • Anti-IL-5Rα
  • Anti-IL-4Rα (dupilumab)
• Last resort: Low-dose oral corticosteroids (≤7.5 mg/day prednisone equivalent) 3
• Alternative for non-type 2 severe asthma: Azithromycin 250-500 mg three times weekly for 26-48 weeks to reduce exacerbations 3
• Procedural option: Bronchial thermoplasty for adults uncontrolled despite optimized treatment 3

Critical Monitoring Parameters

Assessment of asthma control requires evaluation of two domains:

Impairment Domain

• Symptom frequency (daytime and nighttime)
• SABA use frequency (>2 days/week indicates inadequate control) 5
• Limitation of normal activities
• Validated questionnaires: ACT (Asthma Control Test), ACQ (Asthma Control Questionnaire), ATAQ 5

Risk Domain

• Exacerbation frequency: >2 oral corticosteroid bursts in past year indicates poorly controlled asthma 5
• Lung function: FEV1 and FEV1/FVC ratio 5
• Risk factors for asthma-related death include: history of intubation, hospitalization in past year, current/recent oral corticosteroid use, no ICS use, SABA overuse (>1 canister/month), psychiatric illness, poor adherence 3

Diagnostic Confirmation

Before stepping up therapy, confirm the diagnosis using:

• Spirometry demonstrating reversible airflow obstruction (FEV1 improvement ≥12% and ≥200 mL after bronchodilator) 6, 3
• Bronchial provocation testing when FEV1 ≥70% predicted and spirometry is non-diagnostic 3
• FeNO ≥35 ppb with small airway dysfunction and FEV1 improvement ≥10% supports presumptive diagnosis 3
• Peak flow variability ≥20% when spirometry unavailable 3

Key Implementation Points

Before stepping up treatment, systematically address:

1. Inhaler technique (most common cause of treatment failure)
2. Medication adherence
3. Environmental trigger avoidance (allergens, irritants, tobacco smoke)
4. Comorbidities: allergic rhinitis, GERD, obesity, obstructive sleep apnea, anxiety/depression 4, 6

Referral to asthma specialist is indicated when: 5

• Step 4 or higher care required (Step 3 for children 0-4 years)

• 2 oral corticosteroid bursts in 1 year

• Hospitalization for exacerbation
• Considering immunotherapy or biologics
• Difficulty achieving/maintaining control

Common Pitfalls to Avoid

• Never prescribe LABA monotherapy without ICS - this increases mortality risk 7
• SABA-only treatment is obsolete even for mild asthma - it fails to address underlying inflammation and increases exacerbation risk 1, 2
• High-dose ICS monotherapy is inferior to medium-dose ICS-LABA combination for moderate-severe asthma 7, 3
• Long-term high-dose ICS (>recommended range) causes systemic adverse effects: osteoporosis, adrenal suppression, pneumonia risk 3
• Do not rely solely on cutoff values to exclude asthma when clinical suspicion is high - consider presumptive diagnostic treatment trial 3

Special Considerations

Type 2 vs Non-Type 2 Inflammation: 3

• Type 2 (eosinophilic): Elevated blood eosinophils, FeNO, atopy, or total IgE - responds to ICS and biologics
• Non-Type 2: Absence of above markers after excluding infections/medications - may require alternative approaches like azithromycin

Immunotherapy: 3

• Subcutaneous immunotherapy may reduce ICS requirements and improve quality of life in adults
• House dust mite sublingual immunotherapy for HDM-sensitized patients with FEV1 >70% predicted on low-to-medium dose ICS

Follow-up schedule: 3

• Every 2-4 weeks after initial therapy
• Every 1-3 months once response achieved
• Regular inhaler technique training at each visit

The 2020 NAEPP focused updates 4 and 2024 GINA strategy 1, 2 represent the most current evidence-based approach, emphasizing ICS-containing therapy for all patients and MART regimens for moderate-severe disease to optimize outcomes and reduce mortality.